Downregulation of Cyclin Kinase Inhibitors p16INK4a and p27 in Conjunctival Melanomas

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Loss of cyclin-dependent kinase inhibitors (CDKIs) like p16INK4a, p27, and p21 is implicated in melanoma progression.
• Understanding CDKI expression in conjunctival melanocytic proliferations is crucial for diagnosis and treatment strategies.

Purpose of the Study:

• To evaluate the expression of p16INK4a, p27, and p21 in conjunctival nevi, conjunctival melanocytic intraepithelial neoplasia (C-MIN), and conjunctival melanomas (CJMs).
• To explore correlations among genomic, RNA, and protein levels of p16INK4a in CJMs.
• To investigate potential therapeutic strategies by targeting p16INK4a.

Main Methods:

• Immunohistochemistry was used to analyze the expression of p16INK4a, p27, and p21 in 51 conjunctival nevi, 38 C-MIN, and 49 CJMs.
• Whole-genome/exome sequencing and RNA sequencing were performed on CJM samples.
• CJM cell lines were treated with a DNA methyltransferase inhibitor to assess its effect on p16INK4a expression and proliferation.

Main Results:

• Significant downregulation of p16INK4a and p27 was observed in CJMs compared to nevi.
• No CDKN2A mutations were found, but genomic alterations (homozygous/heterozygous loss) and post-transcriptional/post-translational modifications affected p16INK4a expression.
• Treatment with a DNA methyltransferase inhibitor upregulated p16INK4a and reduced proliferation in CJM cell lines.

Conclusions:

• p16INK4a and p27 downregulation in CJMs can aid in histopathological differential diagnosis from conjunctival nevi.
• p16INK4a loss in CJMs is multifactorial, involving genomic, epigenetic, and post-translational mechanisms.
• Restoring p16INK4a function presents a potential therapeutic avenue to reduce CJM aggressiveness.